Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Delayed Swiss Exchange Other stock markets 09:03:56 2025-06-13 am EDT			5-day change	1st Jan Change
97.47 ^CHF	-0.61%		+0.41%	+9.90%

Jun. 12	Swiss Market Index Close Little Changed; Novartis Shares Rise	MT
Jun. 12	Novartis Reports 'Significant' Improvements in Study of Fabhalta to Treat PNH	MT

France's Sanofi to invest at least $20 billion in US through 2030

Published on 05/14/2025 at 13:28

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Novartis AG

Swiss Market Index Close Little Changed; Novartis Shares Rise	Jun. 12	MT
Novartis Reports 'Significant' Improvements in Study of Fabhalta to Treat PNH	Jun. 12	MT
Novartis: Fabhalta approved for a new population	Jun. 12	CF
NOVARTIS AG : Berenberg reiterates its Neutral rating	Jun. 12	ZD
Novartis' Fabhalta Shows Reduced Hemoglobin Levels in Late-stage Trial	Jun. 12	MT
Novartis Says Fabhalta® Shows Statistically Significant And Clinically Meaningful Improvements In Hemoglobin In New Population Of Patients With Pnh	Jun. 12	RE
Novartis Fabhalta(R) shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH	Jun. 12	DJ
EQT, Sanofi Co-Led $135 Million Funding Round for Spanish Biotech Company SpliceBio	Jun. 11	DJ
New purchases in the European Investor portfolio	Jun. 10
NOVARTIS AG : Deutsche Bank gives a Buy rating	Jun. 09	ZD
Otsuka's kidney disease therapy trial results heat up battle with rival Vera	Jun. 06	RE
Further market approval for Formycon's Lucentis biosimilar - share price rises	Jun. 05	DP
Formycon receives market approval in Brazil for Lucentis biosimilar	Jun. 05	DP
Health insurers in favor of cost containment for drug spending	Jun. 03	DP
Swiss Shares in Red as Trade Worries Overtake Q1 GDP Growth Beat	Jun. 02	MT
Novartis Reports New Data From Phase 2 Trial of Kisqali in Breast Cancer	Jun. 02	MT
Novartis Says Pluvicto Shows Benefit in Early Prostate Cancer Study	Jun. 02	MT
Novartis Announces Topline Results from Pre-Specified Interim Analysis of the Phase III PSMAddition Trial	Jun. 02	CI
European Midday Briefing : Stocks Mostly Drop as Trade Tensions Flare	Jun. 02	DJ
Novartis: positive results for two cancer drugs	Jun. 02	CF
Novartis' Pluvicto shown to slow prostate cancer in earlier setting	Jun. 02	RE
Novartis's Cancer Treatment Pluvicto Shows Positive Results in Trial	Jun. 02	DJ
Novartis' Prostate Cancer Treatment Trial Meets Primary Endpoint	Jun. 02	MT
Novartis - Pluvicto Demonstrates Statistically Significant Rpfs Benefit In Patients With Psma-Positive Metastatic Hormone-Sensitive Prostate Cancer	Jun. 02	RE
Novartis Pluvicto(TM) demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer	Jun. 02	DJ

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (29.3%); - immunology (18.5%); - cardiovascular, renal and metabolic diseases (17%); - neuroscience (9.4%). The remaining net sales (25.8%) are from contract manufacturing of pharmaceutical products. At the end of 2024, Novartis AG had over 30 production sites worldwide. Net sales are distributed geographically as follows: Europe (30.9%), the United States (42%), Asia/Africa/Australasia (20%), Canada and Latin America (7.1%).

Employees

75,883

Sector

Pharmaceuticals

Calendar

11:00am - European Hematology Association Congress - Abstract No.: S166

More about the company